Clinical Trial: A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138209) titled 'A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma' on Aug. 13.

Brief Summary: The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Multiple Myeloma

Intervention: DRUG: QLS32015

QLS32015 will be administered subcutaneously.

DRUG: Pomalidomide

Pomalidomide will be administered orally.

DRUG: Selinexor

Selinexor will be ad...